Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children

Abstract

ObjectiveTo observe the clinical effect and adverse reactions of perampanel in the treatment of epilepsy in children.MethodsA retrospective analysis was performed on 83 children with epilepsy who were treated with perampanel in the Department of Pediatric Neurology, Second Affiliated Hospital of Xi'an Jiaotong University from April to August 2021. The treatment status, prognosis and adverse reactions were followed up. The effective rates of different age groups, different seizure types and epilepsy syndromes, and different treatment methods were statistically analyzed. The effective rate and adverse reactions of all patients were statistically analyzed.ResultsThe overall effective rate of perampanel in the treatment of epilepsy was 62.03%, and there was no significant difference in the effective rate of perampanel in the treatment of epilepsy in patients of different ages (P > 0.05). The effective rates of perampanel in the treatment of focal seizures and generalized seizures were 60.38% and 65.38%, and the effective rates of benign childhood epilepsy with centrotemporal spikes (BECT), BECT combined with electrical status epilepticus during sleep (ESES) and frontal lobe epilepsy (FLE) were 88.89, 72.73, and 66.67%. The effective rates of monotherapy and combination therapy were 88.88 and 58.57%, respectively. The above statistical differences were not statistically significant (P > 0.05). In addition, the adverse reaction rate of perampanel treatment was 16.45%, including irritability, drowsiness, dizziness, nausea, vomiting and abnormal liver function.ConclusionPerampanel has a high efficiency and controllable adverse reactions in the treatment of childhood epilepsy. This drug can be used as a reliable choice for long-term use in the treatment of epilepsy in children.

Effectiveness and tolerability of perampanel monotherapy in children with newly diagnosed focal epilepsy

“…The above results suggested that PER monotherapy had generalizability for focal epilepsy with a variety of etiologies in children. In addition, PER monotherapy had higher effective rates for SeLECTs, SeLEAS, and COVE, all of which were more than 80% in our study, which was similar to the previous studies ( 12 ). The lower effective rate of SHE was not discussed because of the small number of cases.…”

“…Future studies need large samples to confirm the effectiveness of PER monotherapy for focal epilepsy in children. Other epilepsy syndromes shown in previous studies, such as Dravet syndrome ( 8 , 12 , 13 ), Lennox–Gastaut syndrome ( 18 – 20 ), and focal epilepsy combined with ESES ( 10 ), presented good effectiveness with PER treatment.…”

“…The lower effective rate of SHE was not discussed because of the small number of cases. Nevertheless, in a recent study with a small sample involving children, PER may also have the potential for treating pediatric SHE ( 12 ). Future studies need large samples to confirm the effectiveness of PER monotherapy for focal epilepsy in children.…”

“…Additionally, PER has a once-daily dosing schedule that supports children's adherence ( 11 ). In previous studies, the effectiveness and tolerability of PER as an add-on or adjunctive treatment for focal epilepsy in children have been demonstrated ( 12 – 14 ). However, the existing data on the effectiveness and tolerability of PER as an initial monotherapy for children with newly diagnosed focal epilepsy are still limited.…”

Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study

“…1,2,[14][15][16] Several studies reported perampanel monotherapy was effective and safe in treating adult and pediatric patients with refractory FOS with or without FBTCS, and most of these studies were retrospective studies. [17][18][19][20][21][22] In China, except for one retrospective study that reported perampanel monotherapy was efficacious and safe in eight of the nine treated pediatric patients with epilepsy, 23 there has been no other published study on the efficacy and safety of perampanel monotherapy in treating FOS. In China, perampanel is currently most used as adjunctive therapy in treating patients with epilepsy as experience in utilizing it for monotherapy is lacking.…”